Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
Read Now: TheBodyPRO.com Covers AIDS 2014
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

Gilead Applies for FDA Approval of Nucleotide Analogue Tenofovir

May 20, 2001

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!


Gilead Sciences has submitted an application for approval to the FDA for the anti-HIV nucleotide analogue reverse transcriptase inhibitor tenofovir. [For more on tenofovir, see Early Access Program Opened for Nucleotide Analogue Tenofovir.] This unexpected announcement means that tenofovir could be approved and available for prescription as early as November of this year. Gilead has also announced that it will relax the criteria for the tenofovir expanded access program. Originally, entrance was restricted to people with CD4 counts less than 100 and viral loads over 10,000. Due to low enrollment, there are now no official CD4 or viral load cut offs, but people must still have documented treatment failure with at least two protease inhibitors (PI) or one PI and one non-nucleoside reverse transcriptase inhibitor (NNRTI). To obtain more information directly from Gilead, call 1-800-Gilead-5.


A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!



  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by Seattle Treatment Education Project. It is a part of the publication STEP Ezine.
 
See Also
More on the FDA Drug Approval Process and Other Regulatory Issues

Tools
 

Advertisement